Search results
May 13, 2022 · Paxlovid has been found to be about 88% effective in preventing hospitalization and death in unvaccinated, high-risk adults with COVID-19.
Apr 15, 2024 · Studies have shown Paxlovid to reduce hospitalization and death by 86% in unvaccinated COVID patients (in initial trials by Pfizer, which developed the drug), and 80% effective in those who have been vaccinated.
Nov 15, 2023 · Official answer. by Drugs.com. Paxlovid lowers the risk of hospitalization or death from COVID-19 by 86% for adult patients who are at high risk of COVID-19 progressing to severe illness when Paxlovid is started within the first 3 days of COVID-19 symptoms.
The US Food and Drug Administration (FDA) approved Paxlovid last May for the treatment of mild to moderate COVID-19 in adults who are at risk of progression to severe disease. But it has been available since early 2022 under Emergency Use Authorization (EUA) from the FDA for treating COVID-19 in people 12 years or older.
Paxlovid has not been approved but has been authorized for emergency use by FDA under an EUA, for the treatment of mild to moderate COVID-19 in adults who are at high-risk for progression to severe COVID-19, including hospitalization or death.
- www.covid19treatmentguidelines.nih.gov
- › Therapies
The COVID-19 Treatment Guidelines Panel (the Panel) recommends using nirmatrelvir 300 mg with ritonavir 100 mg (Paxlovid) orally (PO) twice daily for 5 days in nonhospitalized adults with mild to moderate COVID-19 who are at high risk of disease progression ( AIIa. ).
- www.nih.gov
- › News & Events
- › NIH Research Matters
Jan 10, 2023 · In 2021, a clinical trial found that a combination of the antiviral drugs nirmatrelvir and ritonavir reduced the risk of severe COVID-19 by almost 90% for unvaccinated people. The combination is sold under the name Paxlovid. Today, most of the U.S. population is vaccinated against SARS-CoV-2.
